# Arix Bioscience Analyst Q&A: Investment team very focused and motivated (LON:ARIX)

- Link: https://www.directorstalkinterviews.com/arix-bioscience-analyst-qa-investment-team-very-focused-and-motivated-lonarix/412865240
- Published: 2020-10-19T11:07:55+01:00
- Author: Amilia Stone

**Arix Bioscience plc **(LON:ARIX)is the topic of conversation when **Hardman and
Co**’s Analyst Martin Hall caught up with DirectorsTalk for an exclusive interview.

**Q1: Can you tell us what Arix Bioscience does and how it differs from other investment
vehicles?**

**A1: **They are a listed global venture capital (VC) company that invests solely
in life sciences, or biotech, companies. It provides institutional investors, particularly
those without specialist funds, and retail investors the opportunity to participate
in the high-risk, high-reward, profile associated with early-stage biotech investing.

They minimises the risk through portfolio diversification, stage of product development,
geographical diversification, and internal scientific expertise. Unlike a specialist
closed-end fund where investors are generally locked-in, the company has been set
up as a company with its shares traded on the London market, meaning investors can
readily buy and sell the shares as they wish.

**Q2: The shares of the company have performed well since it released its interim
results for 2020. Can you say what has been behind this movement?**

**A2: **Earlier in the year, they announced a number of changes to streamline its
Board of Directors and reorganise its investment team, with the aim of reducing 
its overall cost base. This was the first set of results for the new management 
team to show its influence, part of which was to highlight the solid internal rate
of return that the company has achieved since inception, reinforce the reduction
in the cost base and to highlight the disconnect between its market capitalisation
and the net asset value (or NAV) of its portfolio.

**Q3: So, how are the shares trading relative to the NAV?**

**A3: **At the interim stage, the management and investment team highlighted that
£149m has been deployed into its portfolio since inception and the NAV had risen
to £251m, giving it an IRR of 20%. The performance in the first half of 2020 was
even better than that overall average, rising 24%. This news resulted in the shares
rising around 35% in the week following results. However, despite this increase,
the market capitalisation is still only around £145m, still lower than the amount
of capital deployed and a 38% discount to NAV.

**Q4: What do you think will make this discount narrow?**

**A4: **First, as part of the internal reorganisation, the investment team has decided
to prioritise its portfolio to focus on the 10-15 companies that offer the highest
potential for value creation. Currently this number is 11 from its overall portfolio
of 16 companies.

Secondly, its portfolio companies are currently involved in about 20 clinical trials
around the world, with several read-outs of results due in the next six-18 months.
These read-outs will all represent significant value inflection points and, on the
law of averages with biotech clinical trials, not all of the outcomes will be successful,
many of them will be. This highlights that the company has multiple opportunities
for NAV appreciation.

Thirdly, the new team has set an aspirational target to make an annual IRR of 15%-
25% and produce a doubling of the NAV to around £500m by the end of 2023. This keeps
the investment team very focused and motivated.

If the team actually achieves something close to these targets, then shareholders
will do very well.

**Q5: What are the risks?**

**A5: **As I mentioned earlier, it is unlikely that all of the ongoing clinical 
trials will be successful, but that is where a diversified portfolio of companies
becomes important.

Portfolio companies are all involved in biotech drug development, which is a capital
intensive business, so there will be future cash calls to support development programmes.
They have a reasonable cash position to support these if it wishes to do so.

A majority of the NAV is from companies which are listed on a stock market. So, 
in theory, the NAV for them changes on a daily basis. Consequently, this could lead
to some volatility in their share price. However, given the large discount that 
it is trading on, it has been fairly stable recently despite some movements, both
upwards and downwards in the share prices of its listed investments.

**Q6: What is coming up in the near future?**

**A6: **As we highlighted in our recent report, most of Arix Bioscience’s investee
companies have good cash runways which will take them beyond an expected value inflection
point. The only one that did not have sufficient cash was LogicBio, and this was
addressed last week with a cash call that the company is supporting.

Also, in that report, which is readily available on the Hardman and Co website, 
we highlighted five investee companies that are expected to have clinical trial 
outcomes and potential value inflection points in the next six months.

Also, given that a number of investee companies are listed, mostly on NASDAQ, there
are quarterly reports which provide investors with updates. Consequently, with its
broad portfolio, the company is rarely out of the news. All of this should see the
NAV discount narrow moving forward.

Share on:
